Tag: plans

CEDARHURST, N.Y., July 21, 2025 (GLOBE NEWSWIRE) -- Postal Realty Trust, Inc. (NYSE: PSTL) (the “Company”), an internally managed real estate investment trust that owns and manages over 2,150 properties leased primarily to the United States Postal Service (the “USPS”), ranging from last-mile post offices to industrial facilities, announced today that its board of directors has approved a quarterly dividend on the Company’s Class A common stock in the amount of $0.2425 per share. This represents a 1.0% increase from the second quarter 2024 dividend. The dividend will be payable on August 29, 2025 to stockholders of record as of the close of business on July 31, 2025.

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra^® for men - in a proprietary topical formulation demonstrated to work where women need it most

Los Angeles, California, July 21, 2025 (GLOBE NEWSWIRE) -- As XRP price breaks through $3.55, returning to the spotlight of top cryptocurrencies, a new wave of investors has turned their attention to a fast-rising but little-known project on the XRP ledger: PBK Miner (PBKMiner XRP Mining).
Given XRP's resilience and strong fundamentals, many XRP holders are now looking to PBK Miner, a next-generation XRP mining program driven by artificial intelligence. By launching a 2-day XRP cloud mining contract, the platform provides investors with a flexible and efficient opportunity to accumulate XRP. The program aims to unlock the market's strong demand for low-threshold, high-liquidity XRP investment products.

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

New York, United States, July 21, 2025 (GLOBE NEWSWIRE) -- Graphjet Technology (“Graphjet” or “the Company”) (Nasdaq:GTI), a leading developer of patented technologies to produce graphite and graphene directly from agricultural waste, is proud to announce that the Company is expecting for new equipment and machineries to arrive in Malaysia by the end of the week.

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases